The discovery of the human immunodeficiency virus (HIV) as the causative agent of the acquired immunodeficiency syndrome (AIDS) has led to enormous efforts to unravel the basic actions of the virus at a molecular level. A variety of targets for potential intervention of HIV multiplication have been outlined in the literature. An essential step for the multiplication and spread of the virus involves reverse transcription of the retroviral RNA to proviral DNA by the enzyme reverse transcriptase (RT). Another promising possibility for interrupting the viral life cycle is the use of inhibitors of the virally encoded protease which is indispensable for viral maturation. The HIV-1 integrase enzyme mediates integration of reverse-transcribed viral DNA into the host genome, an essential step in the life cycle of the virus. The HIV integrase enzyme which is not indigenous to the host presents and attractive target for the development of agents against AIDS. The HIV integrase has been negl ected as a target for quite a long time until; recent developments. We now propose the synthesis of many polyhydroxylated heterocyclic aromatic compounds, with several having secondary degrees of unsaturation and a large variety bearing a flavonoid structure. It is known that flavonoid structures, such as quercetin and caffeic acid phenylethyl ether (CAPE) exhibit cytotoxicity towards tumor cells as well as the HIV virus. We now propose to undertake studies to develop structure-activity relationship (SAR) data on CAPE based compounds as HIV integrase inhibitors. NIH's National Cancer Institute has agreed to conduct in vitro screening for anti-HIV activity for our compounds.

Project Start
2000-09-30
Project End
2001-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
16
Fiscal Year
2000
Total Cost
$80,771
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Type
DUNS #
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Archibong, Edikan; Foster, Alexander; Caldwell, Keirsten et al. (2016) Synthesis, characterization, and electrospinning of novel polyaniline-peptide polymers. Appl Mater Today 4:78-82
Ofori, Edward; Zhu, Xue Y; Etukala, Jagan R et al. (2016) Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. Bioorg Med Chem 24:3464-71
Mathis, Arlesia; Rooks, Ronica; Kruger, Daniel (2016) Improving the Neighborhood Environment for Urban Older Adults: Social Context and Self-Rated Health. Int J Environ Res Public Health 13:ijerph13010003
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9

Showing the most recent 10 out of 204 publications